Skip to main content
Premium Trial:

Request an Annual Quote

Qiagen Licenses Biomarker IP from Johns Hopkins

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Qiagen said today that its DxS subsidiary has licensed a biomarker from Johns Hopkins University that it plans to use to develop PCR-based companion diagnostic tests for cancer.

Studies have shown that the PI3K gene that Qiagen licensed has mutations that could serve as predictive biomarkers for the success of some treatments for patients with lung, breast, colorectal, and other cancers.

The patent for the PI3K was filed by Johns Hopkins researchers who were studying tyrosine kinase inhibitors that target the epidermal growth factor receptor pathway, which has been shown to be useful in treating some cancers.

Qiagen already has on the market a PCR-based test using PI3K that is used for research purposes. The firm said that it has a PI3K assay development and partnering program with pharmaceutical companies to develop and market companion diagnostic tests for cancer drug candidates.

Financial terms of the agreement were not released.

The Scan

Rise of BA.5

The New York Times reports that the Omicron subvariant BA.5 has become the dominant version of SARS-CoV-2 in the US.

UK Health Secretary Resigns

Sajid Javid, the UK health secretary, resigned along with Chancellor Rishi Sunak, saying they cannot work with Prime Minister Boris Johnson's government, CNN reports.

Clones From Freeze-Dried Cells

A team in Japan has cloned mice from freeze-dried skin cells, according to the Guardian.

Genome Research Papers on Craniosynostosis, Macaque Retrotransposition, More

In Genome Research this week: structural variants in craniosynostosis, LINE-1 activity in rhesus macaque brain, and more.